Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Kathy Miller, MD
Indiana University
Principal Investigator - Ted Shih, PharmD
Geron Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
55 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Grand River Regional Cancer Centre
Kitchener, Ontario, Canada
- Stronach Regional Cancer Centre at Southlake
Newmarket, Ontario, Canada
- the Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
- Sunnybrook Health Services Centre
Toronto, Ontario, Canada
- Mcgill University
Montreal, Quebec, Canada
- Clearview Cancer Center
Huntsville, Alabama, United States
- Alta Bates Summit Medical Center
Berkeley, California, United States
- Southbay Oncology Hematology Partners
Campbell, California, United States
- Cancer Care Associates
Fresno, California, United States
- Memorial Miller Hospital
Long Beach, California, United States
- St. Joseph Hospital
Orange, California, United States
- Desert Regional Comprehensive Cancer Center
Palm Springs, California, United States
- Uc San Diego
San Diego, California, United States
- Redwood Regional Medical Group
Santa Rosa, California, United States
- Univ. Colorado at Denver
Aurora, Colorado, United States
- Connecticut Oncology & Hematology
Torrington, Connecticut, United States
- Medical Oncology Hematology
Waterbury, Connecticut, United States
- Florida Oncology Associates
Jacksonville, Florida, United States
- Hematology Oncology Associates
Port Saint Lucie, Florida, United States
- H. Lee Moffitt Cancer Center
Tampa, Florida, United States
- Northeast Georgia Cancer Care
Athens, Georgia, United States
- Emory University
Atlanta, Georgia, United States
- Peachtree Hematology Oncology
Atlanta, Georgia, United States
- Northeast Georgia Medical Center
Gainesville, Georgia, United States
- Central Georgia Cancer Care
Macon, Georgia, United States
- Summit Cancer Care
Savannah, Georgia, United States
- Kootenai Medical Center
Post Falls, Idaho, United States
- Ingalls Memorial Hospital
Chicago, Illinois, United States
- Rush University
Chicago, Illinois, United States
- Mid Illinois Hematology & Oncology
Normal, Illinois, United States
- Cancer Treatment Centers of America
Zion, Illinois, United States
- Community Hospitals of Indiana
Indianapolis, Indiana, United States
- Indiana University
Indianapolis, Indiana, United States
- Horizon Oncology Center
Lafayette, Indiana, United States
- Cancer Center of Kansas
Wichita, Kansas, United States
- Montgomery Cancer Care
Mount Sterling, Kentucky, United States
- Michigan State University
East Lansing, Michigan, United States
- New Mexico Cancer Center
Albuquerque, New Mexico, United States
- Prohealth Associates
Lake Success, New York, United States
- Stony Brook University
Stony Brook, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2010
- Primary completion
- 31 Oct 2012
- Completion
- 31 Dec 2012
- Last update posted
- 26 Jan 2016
- Registered enrollment
- 166
- Registry id
- NCT01256762
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.